Revive TherapeuticsRVVTF
13F holders, Q2 2024 (June 30)2holders −1
0new positions
1sold out
$0.01avg. 13F price*
At the end of Q2 2024, 2 institutions reported holding Revive Therapeutics Ltd. (RVVTF) in their 13F filings, down 1 from Q1 2024. 0 opened new positions and 1 sold out. The largest holders were MAI Capital Management ($188) and FineMark National Bank & Trust ($77).
- Company
- Revive Therapeutics Ltd.
- CUSIP
- 761516103
- Latest filing quarter
- Q1 2026
History
Number of 13F holders
Total Exit/New Position Q1 2024 → Q2 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 1 | $3K |
All 13F filers, Q1 2024 → Q2 2024: 125,000 shares sold, net −125,000 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 2 holders
| MAI Capital Management | 0.00% | No change | 25,000 | $188 |
| FineMark National Bank & Trust | 0.00% | No change | 10,345 | $77 |
"% of holder's portfolio" is RVVTF's weight in each manager's 13F, not the share of Revive Therapeutics Ltd. the manager owns.